Search Menu

Conference reports

BHIVA Autumn conference, 11-12 October 2007, London

Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3

4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney

HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in people interrupting treatment in the SMART trial: new study to randomise people with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3

CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r

Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial

Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results

Importance of using maraviroc in combination with other active drugs in treatment-experienced patients

Week 48 raltegravir results in treatment-naive phase II dose-finding study

DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs

Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r

Saquinavir/r vs lopinavir/r in treatment-naive patients

Fosamprenavir/r vs atazanvir/r in treatment-naive patients

Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study

Very low transmission rates among breastfeeding women receiving ART

Use of pre-exposure prophylaxis (PrEP) by sero-different couples wanting to conceive a child

Increased incidence of miscarriage with efavirenz use

No impact of HSV-2 suppressive therapy on HIV incidence

Penile washing directly after sex increased the risk of acquiring HIV: circumcision effective for men in high prevalence populations no protective effect in gay men

HBV or HCV coinfection produced higher risk from treatment interruptions: drug holidays and hepatitis don’t mix

9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney

Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?

Do children with perinatally acquired HIV infection have problems with metabolism and body shape?

The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?

Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?

Can nucleoside RT inhibitors directly cause insulin resistance?

Do dyslipidemia, insulin resistance, and body shape changes differ according to race or ethnicity?

Is lipoatrophy associated with vascular dysfunction?

XVI International HIV Drug Resistance Workshop, 12-16 June 2007, Barbados

Integrase inhibitors and resistance

Treatment failure and tropism changes in maraviroc trial related to previously undetected CXCR4, rather than a mutational shift from CCR5

Mechanisms of failure to CCR5 inhibitors is not explained by mutation in the V3 loop, cross-resistance between CCR5 inhibitors is likely

Higher risk of resistance using lopinavir/r monotherapy

Macaque study shows similar protection from rectal exposure using 2-hour pre- and 24-hour post exposure prophylaxis with tenofovir plus FTC compared to daily regimen

Thirteen NNRTI mutations linked to resistance to etravirine (TMC-125)

14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles

Protease inhibitors in pregnancy

Low rates of HCV treatment among eligible injection drug users

Effect of HCV and HIV on mortality among injecting drug users

HCV/HIV-co-infected IDUs are at increased risk of death from hepatitis-related death in the HAART era, compared with HCV-mono-IDUs

Long-term effectiveness of isoniazid prophylaxis on TB incidence in a cohort of IDUs

The dynamics of HCV transmission among injection drug users in St. Petersburg

“Founder effect” among HIV-positive IDU in Karachi, Pakistan

8th International Workshop on Clinical Pharmacology of HIV Therapy, April 2007, Budapest, Hungary

Drug-drug interactions

Pharmacokinetic data with existing antiretrovirals

Antiretroviral pharmacokinetics in special patient populations

Pharmacology of investigational drugs

14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles

No benefit of early cessation of breastfeeding in the Zambia Exclusive Breastfeeding Study (ZEBS)

Role of infant feeding and HIV in a severe diarrhoea outbreak in Botswana

Diarrhoea in uninfected infants of HIV-positive mothers who stop breastfeeding at 6 Months

Post-weaning gastroenteritis and mortality in HIV-uninfected infants receiving antiretroviral prophylaxis

Rates of diarrhoea associated with early weaning among infants in the Kisumu breastfeeding study

Early breastfeeding cessation among infants and risk of serious gastroenteritis: findings from a perinatal prevention trial in Kampala, Uganda

Treating children in resource-limited settings

Pharmacokinetics of nevirapine, d4T, and 3TC in Zambian children treated with Pedimune (Triomune)

New PK data for protease inhibitors

Plasma concentrations of efavirenz and lopinavir in children with and without rifampicin-based TB treatment

NNRTI vs PI HAART regimens for children in resource-limited settings

Predictors of infant mortality

HIV-infection in the brain, neurocognitive dysfunction and CNS drug penetration

Selected genetics studies from CROI

Report from genomics workshop at CROI

5th European HIV Drug Resistance Workshop, Cascais, Portugal, 29 March 2007

Post navigation